Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions: MCS110, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more

Conditions: Alcohol; Use, Problem
Interventions: Experimental: Mobile Alcohol Expectancy Intervention; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 25 Years
Enrollment: 408 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Myocardial Infarct
Interventions: RNS60, Placebo; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Chickenpox
Interventions: Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 911 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more

Conditions: Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
Interventions: Allopurinol, Placebo; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Energy Expenditure
Interventions: One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350), Caffeine, Placebo; Dietary Supplement · Drug
Lead sponsor: Bayer; Industry
Eligibility: 25 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Bacterial Infections
Interventions: XNW4107; Drug
Lead sponsor: Evopoint Biosciences Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PreDiabetes
Interventions: Real time continuous glucose monitor (Stelo); Device
Lead sponsor: Young Men's Christian Association of the Blue Water Area; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Port Huron, Michigan

Conditions: Healthy Subjects
Interventions: Placebo, E2609, Moxifloxacin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: Danicamtiv, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Alzheimer's Disease, Healthy Volunteer
Interventions: [11C]RO6924963, [11C]RO6931643, [18F]RO6958948; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: mipomersen sodium, moxifloxacin hydrochloride (Avelox®), placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Unhealthy Alcohol Use
Interventions: Contingency Management Counseling, Addiction Physician Management, Motivational Enhancement Therapy; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: Obesity
Interventions: Genetic, Lifestyle; Genetic · Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 798 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Depression
Interventions: Men's Healing Pathways; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Low Back Pain
Interventions: Chiropractic manipulative therapy; Procedure
Lead sponsor: Ian Coulter; Other
Eligibility: 18 Years to 40 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Pensacola, Florida

Conditions: Osteoarthritis, Knee
Interventions: Placebo, CNTX-4975-05; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 30
States / cities: Glendale, Arizona • Phoenix, Arizona • Carmichael, California + 23 more

Conditions: Obesity, Overweight
Interventions: VA MapTrek, Fitbit Only; Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 100 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pain, Hip Fractures
Interventions: Femoral Nerve Block; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: New York, New York

Conditions: Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
Interventions: Standard of Care, Revita, Relese, Cogenex, Enverse; Other
Lead sponsor: StimLabs; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Omaha, Nebraska • Tulsa, Oklahoma • Jefferson Hills, Pennsylvania + 2 more

Conditions: Prostate Cancer
Interventions: MR-Guided Transurethral US Ablation of Prostate Tissue; Device
Lead sponsor: Profound Medical Inc.; Other
Eligibility: 65 Years to 75 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Multiple Myeloma
Interventions: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs), Standard of care; Biological · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Alcohol & Mobile Phone Study to Reduce High-risk Alcohol Use and Consequences

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Allopurinol Add-on Treatment for Refractory Mania

Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

The YMCA Healthy Lifestyle Program for Prediabetes

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Financial Incentives, Randomization With Stepped Treatment Trial

Communicating Risk Information for Obesity

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

Depression in Men With Physical Disabilities

Assessment of Chiropractic Treatment: Strength and Balance

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

Increasing Steps Per Day in Rural Veterans

Improving Pain and Function in Hip Fracture

Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs

Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation